HYPER-CVAD regimen

	WikiDoc Resources for HYPER-CVAD regimen
Articles
Most recent articles on HYPER-CVAD regimen Most cited articles on HYPER-CVAD regimen Review articles on HYPER-CVAD regimen Articles on HYPER-CVAD regimen in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on HYPER-CVAD regimen Images of HYPER-CVAD regimen Photos of HYPER-CVAD regimen Podcasts & MP3s on HYPER-CVAD regimen Videos on HYPER-CVAD regimen
Evidence Based Medicine
Cochrane Collaboration on HYPER-CVAD regimen Bandolier on HYPER-CVAD regimen TRIP on HYPER-CVAD regimen
Clinical Trials
Ongoing Trials on HYPER-CVAD regimen at Clinical Trials.gov Trial results on HYPER-CVAD regimen Clinical Trials on HYPER-CVAD regimen at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on HYPER-CVAD regimen NICE Guidance on HYPER-CVAD regimen NHS PRODIGY Guidance FDA on HYPER-CVAD regimen CDC on HYPER-CVAD regimen
Books
Books on HYPER-CVAD regimen
News
HYPER-CVAD regimen in the news Be alerted to news on HYPER-CVAD regimen News trends on HYPER-CVAD regimen
Commentary
Blogs on HYPER-CVAD regimen
Definitions
Definitions of HYPER-CVAD regimen
Patient Resources / Community
Patient resources on HYPER-CVAD regimen Discussion groups on HYPER-CVAD regimen Patient Handouts on HYPER-CVAD regimen Directions to Hospitals Treating HYPER-CVAD regimen Risk calculators and risk factors for HYPER-CVAD regimen
Healthcare Provider Resources
Symptoms of HYPER-CVAD regimen Causes & Risk Factors for HYPER-CVAD regimen Diagnostic studies for HYPER-CVAD regimen Treatment of HYPER-CVAD regimen
Continuing Medical Education (CME)
CME Programs on HYPER-CVAD regimen
International
HYPER-CVAD regimen en Espanol HYPER-CVAD regimen en Francais
Business
HYPER-CVAD regimen in the Marketplace Patents on HYPER-CVAD regimen
Experimental / Informatics
List of terms related to HYPER-CVAD regimen

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]

Synonyms and keywords: Hyper-Cyclophosphamide-Vincristine-Adriamycin-Dexamethasone regimen

Overview

HYPER-CVAD regimen refers to a regimen consisting of cyclophosphamide, vincristine, doxorubicin (Adriamycin), and dexamethasone used to treat some forms of Burkitt's lymphoma, diffuse large B-cell lymphoma, and multiple myeloma.^[1]^[2]^[3]

Regimen

CCyclophosphamide

VVincristine (Oncovin)

ADoxorubicin (Adriamycin)

DDexamethasone

Indications

References

↑ ^1.0 ^1.1 Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Navarro Coy N; et al. (2012). "Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results". Haematologica. 97 (3): 442–50. doi:10.3324/haematol.2011.043372. PMC 3291601. PMID 22058209.
↑ ^2.0 ^2.1 Oki Y, Westin JR, Vega F, Chuang H, Fowler N, Neelapu S; et al. (2013). "Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma". Br J Haematol. 163 (5): 611–20. doi:10.1111/bjh.12585. PMID 24117234.
↑ ^3.0 ^3.1 Thomas DA, Faderl S, O'Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G; et al. (2006). "Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia". Cancer. 106 (7): 1569–80. doi:10.1002/cncr.21776. PMID 16502413.

[pmid22058209-1] 1.0 ^1.1 Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Navarro Coy N; et al. (2012). "Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results". Haematologica. 97 (3): 442–50. doi:10.3324/haematol.2011.043372. PMC 3291601. PMID 22058209.

[pmid24117234-2] 2.0 ^2.1 Oki Y, Westin JR, Vega F, Chuang H, Fowler N, Neelapu S; et al. (2013). "Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma". Br J Haematol. 163 (5): 611–20. doi:10.1111/bjh.12585. PMID 24117234.

[pmid16502413-3] 3.0 ^3.1 Thomas DA, Faderl S, O'Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G; et al. (2006). "Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia". Cancer. 106 (7): 1569–80. doi:10.1002/cncr.21776. PMID 16502413.

[1]

[2]

[3]

HYPER-CVAD regimen

Overview

Regimen

Indications

References

Navigation menu

Search